azd9550
Peptideexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 2, 2023 (NCT05848440)
Timeline
Indications
Mechanism of action
GLP1R agonist
Amylin receptor AMY1, CALCR/RAMP1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07017179 | Phase 2 | May 20, 2025 | AstraZeneca |
| NCT06862791 | Phase 2 | Feb 18, 2025 | AstraZeneca |
| NCT06151964 | Phase 1/Phase 2 (Phase 2) | Sep 29, 2023 | AstraZeneca |
| NCT05848440 | Phase 1 | May 2, 2023 | AstraZeneca, Parexel |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2023 |
| Parexel | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1